Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Two out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 68 points (0.4%) at 17,048 as of Thursday, Aug. 21, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,747 issues advancing vs. 1,215 declining with 171 unchanged. The Drugs industry currently sits down 0.9% versus the S&P 500, which is up 0.3%. Top gainers within the industry include AstraZeneca ( AZN), up 2.6%, and Teva Pharmaceutical Industries ( TEVA), up 0.8%. On the negative front, top decliners within the industry include Mylan ( MYL), down 1.5%, Merck ( MRK), down 0.7% and Biogen Idec ( BIIB), down 0.6%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. Actavis ( ACT) is one of the companies pushing the Drugs industry higher today. As of noon trading, Actavis is up $3.89 (1.7%) to $227.25 on average volume. Thus far, 1.2 million shares of Actavis exchanged hands as compared to its average daily volume of 2.5 million shares. The stock has ranged in price between $223.52-$228.12 after having opened the day at $227.00 as compared to the previous trading day's close of $223.36. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. Actavis plc, an integrated specialty pharmaceutical company, is engaged in the development, manufacture, marketing, sale, and distribution of pharmaceutical products in the Americas, Europe, the Middle East, Africa, Australia, and the Asia Pacific. Actavis has a market cap of $59.0 billion and is part of the health care sector. Shares are up 33.0% year-to-date as of the close of trading on Wednesday. Currently there are 16 analysts who rate Actavis a buy, no analysts rate it a sell, and none rate it a hold. TheStreet Ratings rates Actavis as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, compelling growth in net income and good cash flow from operations. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full Actavis Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.